VivoSim Labs, Inc. Equity Securities, FV-NI, Realized Loss
VivoSim Labs, Inc. (VIVS) reported Equity Securities, FV-NI, Realized Loss of $5.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedLoss · last filed 2022-08-11
- VivoSim Labs, Inc. equity securities, fv-ni, realized loss for the quarter ending 2022-06-30 was $5.00K.
| Period end | Equity Securities, FV-NI, Realized Loss 3 month |
|---|---|
| 2022-06-30 | $5.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |